Benzinga · Nov 13, 2026
Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13
Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.
NASDAQ · CRMD
Healthcare · Biotechnology
$5.27
Up+$0.19 (+3.74%)
Updated Nov 21, 2026, 9:23 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CRMD
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 20, 2026
CRMD closed at $5.27 after 21 trading sessions, down 32.87% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 20, 2026 | $4.96 | $5.315 | $4.95 | $5.27 | 3.61M |
| Nov 19, 2026 | $4.57 | $5.155 | $4.465 | $5.08 | 3.55M |
| Nov 18, 2026 | $4.65 | $4.71 | $4.485 | $4.50 | 1.6M |
| Nov 17, 2026 | $4.79 | $4.87 | $4.635 | $4.67 | 1.99M |
| Nov 16, 2026 | $5.05 | $5.2331 | $4.75 | $4.82 | 3.2M |
| Nov 13, 2026 | $4.88 | $5.055 | $4.65 | $4.66 | 2.39M |
| Nov 12, 2026 | $5.15 | $5.49 | $4.815 | $4.84 | 3.68M |
| Nov 11, 2026 | $5.33 | $5.42 | $5.24 | $5.30 | 1.63M |
| Nov 10, 2026 | $5.49 | $5.675 | $5.29 | $5.37 | 2.34M |
| Nov 9, 2026 | $5.47 | $5.56 | $5.16 | $5.47 | 2.33M |
| Nov 6, 2026 | $5.25 | $5.335 | $5.10 | $5.32 | 1.62M |
| Nov 5, 2026 | $5.75 | $5.77 | $5.2114 | $5.23 | 1.83M |
| Nov 4, 2026 | $5.71 | $5.79 | $5.58 | $5.66 | 1.49M |
| Nov 3, 2026 | $5.35 | $5.60 | $5.30 | $5.56 | 2.46M |
| Nov 2, 2026 | $5.70 | $5.75 | $5.34 | $5.39 | 3.3M |
| Oct 30, 2026 | $7.68 | $7.68 | $5.63 | $5.695 | 7.02M |
| Oct 29, 2026 | $8.34 | $8.3545 | $7.455 | $7.64 | 1.89M |
| Oct 28, 2026 | $7.95 | $8.22 | $7.90 | $8.20 | 1.16M |
| Oct 27, 2026 | $7.91 | $8.11 | $7.80 | $8.00 | 1M |
| Oct 26, 2026 | $8.06 | $8.09 | $7.7622 | $7.94 | 1.13M |
| Oct 23, 2026 | $8.01 | $8.11 | $7.79 | $7.85 | 894.54K |
The latest Smart Investors Daily articles mentioning CRMD.
Company
Market Activity
Research & News
CRMD research
Company profile and research snapshot.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 13, 2026 | RBC Capital | Outperform | — |
| Nov 13, 2026 | Oppenheimer | Outperform | — |
| Nov 12, 2026 | Needham | Buy | — |
| Nov 10, 2026 | RBC Capital | Outperform | — |
| Nov 10, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 13, 2026
Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.
Benzinga · Nov 13, 2026
RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $14.
Yahoo · Nov 12, 2026
Heron deal and DefenCath reimbursement shifts drive the quarter.
SeekingAlpha · Nov 12, 2026
CorMedix Inc. (CRMD) Q3 2026 Earnings Call November 12, 2026 8:30 AM ESTCompany ParticipantsJoseph Todisco - CEO & Chairman of the Board of...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning CRMD.